# Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

> **NCT06573294** · PHASE1 · TERMINATED · sponsor: **Genmab** · enrollment: 23 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors
- Metastatic Malignant Solid Tumors

## Interventions

- **DRUG:** GEN1057
- **DRUG:** Premedication

## Key facts

- **NCT ID:** NCT06573294
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-28
- **Primary completion:** 2026-04-08
- **Final completion:** 2026-04-08
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not supporting further development
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573294, "Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT06573294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*